Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review

Value in Health

Volumn 21, Issue 7, 2018, Pages 881-890

  Einarson, Thomas R ^a   Acs, Annabel ^b   Ludwig, Craig ^b   Panton, Ulrik H ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Last Mile P   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

cardiovascular disease; coronary artery disease; cost; ischemic heart disease; stroke

Indexed keywords

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONSUMER; CORONARY ARTERY DISEASE; COST OF ILLNESS; DISEASE BURDEN; ECONOMIC ASPECT; HEALTH CARE COST; HEART FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; ECONOMIC MODEL; ECONOMICS; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMORBIDITY; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MODELS, ECONOMIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85042016886     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.12.019     Document Type: Review

References (64)

1. International Diabetes Federation. IDF Diabetes Atlas, 7th ed., 2015, International Diabetes Federation, Brussels, Belgium.
2. Bommer, C., Heesemann, E., Sagalova, V., et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 5 (2017), 423–430.
3. Einarson TR, Bereza BG, Acs A, et al. PDB9: prevalence of cardiovascular disease in type 2 diabetes: a global systematic review. Presented at: ISPOR 20th Annual European Congress, Glasgow, Scotland, 2017.
4. Sarwar, N., Gao, P., Seshasai, S.R., et al., Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
5. Peters, S.A., Huxley, R.R., Woodward, M., Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57 (2014), 1542–1551.
6. Dinesh Shah, A., Langenberg, C., Rapsomaniki, E., et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet, 385(Suppl. 1), 2015, S86.
7. International Diabetes Federation. Diabetes and Cardiovascular Disease. 2016, International Diabetes Federation, Brussels, Belgium.
8. Diabetes UK. Diabetes in the UK 2012: keystatisticsondiabetes. Available from: https://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2012.pdf. [Accessed March 17, 2017].
9. Hu, F.B., Stampfer, M.J., Solomon, C.G., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 161 (2001), 1717–1723.
10. Hex, N., Bartlett, C., Wright, D., et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 29 (2012), 855–862.
11. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care 36 (2013), 1033–1046.
12. Kontopantelis, E., Springate, D.A., Reeves, D., et al. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia 58 (2015), 505–518.
13. Li, W., Katzmarzyk, P.T., Horswell, R., et al. HbA1c and all-cause mortality risk among patients with type 2 diabetes. Int J Cardiol 202 (2016), 490–496.
14. American Diabetes Association. Standards of medical care in diabetes care. Diabetes Care 40 (2017), S1–S42.
15. Phung, O., Schwartzman, E., Allen, R., et al. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 30 (2013), 1160–1171.
16. Schnell, O., Rydén, L., Standl, E., et al. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol, 16, 2017, 128.
17. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008, US Department of Health and Human Services, Washington, DC.
18. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
19. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
20. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
21. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
22. Goeree, R., Morgan, E., Lim, M.A., et al. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can. J Diabetes 33 (2009), 35–45.
23. Colin, X., Lafuma, A., Gueron, B., Costs of cardiovascular events of diabetic patients in the French hospitals. Diabetes Metab 33 (2007), 310–313.
24. Vaidya, V., Gangan, N., Sheehan, J., Impact of cardiovascular complications among patients with type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res 15 (2015), 487–497.
25. University of Illinois at Chicago. Evidence based medicine: PICO. Available from: http://researchguides.uic.edu/c.php?g=252338&p=3954402. [Accessed May 14, 2017].
26. United States Federal Reserve. Foreign exchange rates. Available from: https://www.federalreserve.gov/Releases/H10/Hist/. [Accessed March 8, 2017].
27. Akobundu, E., Ju, J., Blatt, L., et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 24 (2006), 869–890.
28. Drummond, M., Jefferson, T., Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313 (1996), 275–283.
29. Nanwa, N., Kendzerska, T., Krahn, M., et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol 110 (2015), 511–519.
30. Pelone, F., Specchia, M.L., Veneziano, M.A., et al. Economic impact of childhood obesity on health systems: a systematic review. Obes Rev 13 (2012), 431–440.
31. Luengo-Fernandez, R., Gray, A.M., Rothwell, P.M., Costs of stroke using patient-level data: a critical review of the literature. Stroke 40 (2009), e18–e23.
32. Hnoosh, A., Babineaux, S.M., Piras de Oliveira, C., et al. Direct costs of type 2 diabetes from the Brazilian Public Health Care sector. Value Health, 16, 2013, A689.
33. Saric, T., Benkovic, V., Poljicanin, T., et al. Cost of diabetes in Croatia: impact of complications on the costs of type II diabetes. Value Health, 14, 2011, A477.
34. Chatzitheofilou, I., Babineaux, S., Ramírez-Gámez, J., et al. Direct costs of type 2 diabetes in Mexico from the public health care sector perspective. Value Health 16 (2013), A688–A689.
35. Alva, M.L., Gray, A., Mihaylova, B., et al. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med 32 (2015), 459–466.
36. Bahia, L.R., Araujo, D.V., Schaan, B.D., et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health 14 (2011), S137–S140.
37. Candrilli, S., Meyers, J., Boye, K., et al. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications 29 (2015), 529–533.
38. Carls, G.S., Tan, R.D., Frois, C., et al. A regimen-based measure of adherence and its association with healthcare costs in patients with type 2 diabetes and patients with both cardiovascular disease and type 2 diabetes mellitus. Diabetologia, 58, 2015, S25.
39. Fukuda, H., Ikeda, S., Shiroiwa, T., et al. Medical expenditures associated with type 2 diabetes mellitus in Japan: a large claims database study. Value Health, 17, 2014, A341.
40. Govan, L., Wu, O., Briggs, A., et al. Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 54 (2011), 2000–2008.
41. Hyland, K.A., Greiner, M., Qualls, L., et al. The importance of heart failure on the outcomes and health care costs of Medicare patients with type 2 diabetes. Diabetes, 63, 2014 A348-A48.
42. Johnston, S., Shah, M., Sheehan, J., et al. Cost of major adverse cardiac events (MACE) among type 2 diabetes mellitus (T2DM) patients with obesity, renal impairment, or varying cardiovascular risk. Diabetes, 63, 2014, A619.
43. Kim, T.H., Chun, K.H., Kin, H.J., et al. Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program. J Korean Med Sci 27 (2012), 976–982.
44. Kumpatla, S., Kothandan, H., Tharkar, S., et al. The costs of treating long-term diabetic complications in a developing country: a study from India. J Assoc Physicians India 61 (2013), 102–109.
45. Li, R., Bilik, D., Brown, M.B., et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 19 (2013), 421–430.
46. Männik, A., Pisarev, H., Kiivet, R., Type II diabetes complications’ cost in Estonia. Value Health, 18, 2015, A603.
47. Mata-Cases, M., Casajuana, M., Franch-Nadal, J., et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. Eur J Health Econ 17 (2016), 1001–1010.
48. Meléndez, G., Cabra, H., Zanela, O., et al. Cost of type 2 diabetes complications in Mexico. Value Health, 12, 2009, A505.
49. Mody, R., Kalsekar, I., Kavookjian, J., et al. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diabetes Complications 21 (2007), 75–83.
50. Pagano, E., Bo, S., Petrinco, M., et al. Factors affecting hospitalization costs in type 2 diabetic patients. J Diabetes Complications 23 (2009), 1–6.
51. Pelletier, E.M., Smith, P.J., Boye, K.S., et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting. Appl Health Econ Health Policy 6 (2008), 103–112.
52. Ringborg, A., Yin, D.D., Martinell, M., et al. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil 16 (2009), 576–582.
53. Ward, A., Alvarez, P., Vo, L., et al. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 17 (2014), 176–183.
54. Yeaw, J., Halinan, S., Hines, D., et al. Direct medical costs for complications among adults with type 2 diabetes in a US commercial payer setting. Value Health, 16, 2013, A190.
55. Straka, R.J., Liu, L.Z., Girase, P.S., et al. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol, 8, 2009, 53.
56. Hubert, H.B., Feinleib, M., McNamara, P.M., et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67 (1983), 968–977.
57. Druss, B.G., Marcus, S.C., Olfson, M., et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood) 20 (2001), 233–241.
58. Magnan, E.M., Palta, M., Mahoney, J.E., et al. The relationship of individual comorbid chronic conditions to diabetes care quality. BMJ Open Diabetes Res Care, 3, 2015, e000080.
59. Teljeur, C., Smith, S.M., Paul, G., et al. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract 19 (2013), 17–22.
60. Struijs, J.N., Baan, C.A., Schellevis, F.G., et al. Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC Health Serv Res, 6, 2006, 84.
61. Piette, J.D., Kerr, E.A., The impact of comorbid chronic conditions on diabetes care. Diabetes Care 29 (2006), 725–731.
62. Salisbury, C., Multimorbidity: redesigning health care for people who use it. Lancet 380 (2012), 7–9.
63. Laiteerapong, N., Huang, E.S., Chin, M.H., Prioritization of care in adults with diabetes and comorbidity. Ann N Y Acad Sci 1243 (2011), 69–87.
64. Rydén, L., Grant, P.J., Anker, S.D., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab Vasc Dis Res 11 (2014), 133–173.